Oregon — Attorney General Dan Rayfield announced that Oregon and 47 other states and territories have reached two settlements totaling $17.85 million with Lannett Company, Inc. and Bausch Health US, LLC and Bausch Health Americas, Inc..
The agreements resolve allegations that the companies engaged in long-running conspiracies to inflate prices, restrict competition and manipulate the market for numerous generic prescription drugs between 2009 and 2019. The companies did not admit wrongdoing as part of the settlements.
Under the terms, Lannett and Bausch will pay a combined $17.85 million and cooperate with ongoing multistate litigation led by Connecticut against 30 corporate defendants and 25 individual executives. Both companies also agreed to internal compliance reforms aimed at strengthening antitrust oversight.
Rayfield said generic drugs are often the most affordable option for families and that collusion undermines competition and raises healthcare costs.
The settlements follow earlier agreements with Apotex and Heritage totaling $49.1 million. States are preparing for the first trial in the broader case, expected in late 2026 in Hartford, Connecticut.
Separately, Oregon and 41 other states filed a new lawsuit against Novartis and its generic subsidiary Sandoz, alleging a coordinated effort to fix prices, allocate markets and rig bids for 31 generic drugs. The complaint also alleges that Novartis improperly transferred assets from Sandoz to shield itself from potential liability in earlier antitrust cases.
The broader investigation is based on millions of documents and phone records, as well as testimony from cooperating witnesses within the generic drug industry.
Consumers who purchased generic drugs manufactured by Lannett or Bausch between May 2009 and December 2019 may be eligible for compensation through the multistate settlement process.
The litigation remains ongoing.
About the Author
Discover more from Right Now Oregon
Subscribe to get the latest posts sent to your email.
